Literature DB >> 2875883

Comparison of the effects of fenoldopam, SK & F R-87516 and dopamine on renal arterioles in vitro.

R M Edwards.   

Abstract

The ability of the selective DA1 agonists fenoldopam and SK & F R-87516 to relax norepinephrine-contracted afferent and efferent arterioles isolated from rabbit kidney was compared. In both arterioles, fenoldopam and SK & F R-87516 produced a concentration-dependent relaxation with a potency similar to that of dopamine. Fenoldopam also relaxed efferent arterioles contracted with angiotensin II. The selective DA1 receptor antagonist, SK & F R-83566, caused parallel displacements in the concentration-response curves to SK & F 82526, corresponding to dissociation constants of 10.5 and 8.3 nM for afferent and efferent arterioles, respectively. The results provide direct evidence that the dopamine receptor present on renal resistance vessels is of the DA1 subtype.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2875883     DOI: 10.1016/0014-2999(86)90756-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

Review 1.  Can the use of low-dose dopamine for treatment of acute renal failure be justified?

Authors:  C J Burton; C R Tomson
Journal:  Postgrad Med J       Date:  1999-05       Impact factor: 2.401

2.  The action of dopamine and vascular dopamine (DA1) receptor agonists on human isolated subcutaneous and omental small arteries.

Authors:  A D Hughes; P S Sever
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

3.  Dopamine D1 receptor (DRD1) genetic polymorphism: pleiotropic effects on heritable renal traits.

Authors:  Maple M Fung; Brinda K Rana; Chih-Min Tang; Tetsuo Shiina; Caroline M Nievergelt; Fangwen Rao; Rany M Salem; Jill Waalen; Michael G Ziegler; Paul A Insel; Daniel T O'Connor
Journal:  Kidney Int       Date:  2009-08-12       Impact factor: 10.612

4.  Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.

Authors:  Victoria K Snowdon; Neil J Lachlan; Anna M Hoy; Patrick W F Hadoke; Scott I Semple; Dilip Patel; Will Mungall; Timothy J Kendall; Adrian Thomson; Ross J Lennen; Maurits A Jansen; Carmel M Moran; Antonella Pellicoro; Prakash Ramachandran; Isaac Shaw; Rebecca L Aucott; Thomas Severin; Rajnish Saini; Judy Pak; Denise Yates; Neelesh Dongre; Jeremy S Duffield; David J Webb; John P Iredale; Peter C Hayes; Jonathan A Fallowfield
Journal:  PLoS Med       Date:  2017-02-28       Impact factor: 11.069

Review 5.  Renal oxygenation in clinical acute kidney injury.

Authors:  Sven-Erik Ricksten; Gudrun Bragadottir; Bengt Redfors
Journal:  Crit Care       Date:  2013-03-19       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.